select a format

Single User License
USD 250 INR 16045
Site License
USD 500 INR 32090
Corporate User License
USD 750 INR 48135

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Alembic Pharmaceuticals Ltd (APLLTD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Alembic Pharmaceuticals Ltd (APLLTD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH51841D
  • |
  • Pages: 24
  • |
  • April 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Alembic Pharmaceuticals Ltd (Alembic Pharma) is a pharmaceutical company that develops, manufactures and markets pharmaceutical products, pharmaceutical substances and intermediates. The company offers active pharmaceutical ingredients including macrolides, NSAIDs, and other drugs. It also offers branded formulations in the areas of antibiotics and antibacterial, cardiovascular, gynecological, cough and cold, gastroenterological, ophthalmological, anti-diabetic, orthopedic, urology, antihistamine, dermatological, and herbal nutraceuticals. Alembic Pharma provides generic formulations such as anti-allergic, anthelmintic, antimicrobials, antiulcerants, nutritional and vitamin preparations and others speciality products. The company operates its manufacturing facilities in Vadodara, Gujarat and Baddi, Himachal Pradesh. Alembic Pharma is headquartered in Vadodara, Gujarat, India.

Alembic Pharmaceuticals Ltd (APLLTD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Alembic Pharma to Form Joint Venture with Orbicular Pharma 10

TG Therapeutics Enters Into Agreement With Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 10

Licensing Agreements 12

TG Therapeutics Exercises Option for Licensing Agreement with Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 12

Novartis Enters into Licensing Agreement with Rhizen Pharma 13

Ranbaxy Pharma Enters Into Licensing Agreement With Alembic Pharma For Desvenlafaxine Base Extended-Release Tablets 14

Accu-Break Pharma Enters Into Licensing Agreement With Alembic Pharma To Develop Novel Pharma Products 14

Acquisition 15

Alembic Pharma to Acquire 49% Stake in Adwiya Mami 15

Alembic Pharmaceuticals Ltd-Key Competitors 17

Key Employees 18

Locations And Subsidiaries 19

Head Office 19

Other Locations & Subsidiaries 19

Recent Developments 21

Financial Announcements 21

Apr 27, 2016: Alembic Pharmaceuticals reported its audited financial results for the year ending 31st March 2016 21

Legal and Regulatory 23

Mar 10, 2017: Alembic Pharmaceuticals Announces US FDA Inspection at Baroda Facility 23

Appendix 24

Methodology 24

About GlobalData 24

Contact Us 24

Disclaimer 24

List of Figures

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

List of Tables

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Alembic Pharmaceuticals Ltd, Deals By Therapy Area, 2011 to YTD 2017 8

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Alembic Pharma to Form Joint Venture with Orbicular Pharma 10

TG Therapeutics Enters Into Agreement With Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 10

TG Therapeutics Exercises Option for Licensing Agreement with Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 12

Novartis Enters into Licensing Agreement with Rhizen Pharma 13

Ranbaxy Pharma Enters Into Licensing Agreement With Alembic Pharma For Desvenlafaxine Base Extended-Release Tablets 14

Accu-Break Pharma Enters Into Licensing Agreement With Alembic Pharma To Develop Novel Pharma Products 14

Alembic Pharma to Acquire 49% Stake in Adwiya Mami 15

Alembic Pharmaceuticals Ltd, Key Competitors 17

Alembic Pharmaceuticals Ltd, Key Employees 18

Alembic Pharmaceuticals Ltd, Other Locations 19

Alembic Pharmaceuticals Ltd, Subsidiaries 19

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com